## The pulmonary mycobiome - a study of subjects with and without chronic obstructive pulmonary disease

**Supporting Information, S3 Fig** 

Einar M. H. Martinsen<sup>1\*</sup>, Tomas M. L. Eagan<sup>1,2</sup>, Elise O. Leiten<sup>1</sup>, Ingvild Haaland<sup>1</sup>, Gunnar R. Husebø<sup>1,2</sup>, Kristel S. Knudsen<sup>2</sup>, Christine Drengenes<sup>1,2</sup>, Walter Sanseverino<sup>3</sup>, Andreu Paytuví-Gallart<sup>3</sup>, and Rune Nielsen<sup>1,2</sup>

<sup>1</sup>Department of Clinical Science, University of Bergen, Bergen, Norway

<sup>2</sup>Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway


<sup>3</sup>Sequentia Biotech SL, Barcelona, Spain

\* Corresponding author


E-mail: einar.martinsen@uib.no

## S3 Fig. Principal coordinates analysis plots by (A) study group and (B) inhaled steroids use.

**(A)** 



**(B)** 



Differences in beta diversity were tested with permuted analysis of variance (PERMANOVA) adjusted for sex, age, and percentage of predicted  $FEV_1$  (permutations = 10000). No significant differences were seen in spread/dispersion (permutations = 1000).